Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MLYCD | O95822 | 2/20 | 0.51 |
| ▸ | ESRRG | P62508 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 3/20 | 0.50 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | CCND1 | P24385 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211819 | 0.84 | MMP13 (0.84) | MMP13NPC1RAB9ASMN1; SMN2MLYCD | |
| SCHEMBL257847 | 0.84 | MLYCD (0.69) | NPC1RAB9AMLYCDESRRGNAMPT | |
| SCHEMBL15317659 | 0.84 | ESRRG (0.73) | MMP13SMN1; SMN2MLYCDESRRGNAMPT | |
| SCHEMBL17888312 | 0.83 | NAMPT (0.57) | MMP13MLYCDNAMPTCDK4CCND1 | |
| SCHEMBL4387675 | 0.77 | CYP1A2 (0.45) | MMP13NPC1RAB9ASMN1; SMN2MLYCD | |
| SCHEMBL4487134 | 0.77 | CYP1A2 (0.53) | MMP13NPC1RAB9ASMN1; SMN2MLYCD | |
| SCHEMBL11172152 | 0.77 | NAMPT (0.45) | MMP13NPC1RAB9ASMN1; SMN2NAMPT | |
| SCHEMBL12155870 | 0.76 | TSHR (0.44) | NPC1RAB9ASMN1; SMN2MLYCDESRRG | |
| SCHEMBL7973811 | 0.76 | LOXL2 (0.44) | MMP13NPC1RAB9ASMN1; SMN2MLYCD | |
| SCHEMBL7973810 | 0.76 | CYP1A2 (0.44) | MMP13NPC1RAB9ASMN1; SMN2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MMP13 3952/4885NPC1 3586/4885RAB9A 3888/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | MMP13 3952/4885NPC1 3586/4885RAB9A 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.